Article ; Online: Les CAR-NK allogéniques : une alternative prometteuse aux CAR-T autologues – État de la question, sources de cellules NK, limites et perspectives.
2021 Volume 108, Issue 10S, Page(s) S81–S91
Abstract: Immunotherapy with chimeric antigen receptor engineered-T cells (CAR-T) has revolutionized the landscape of treatment of relapsed or refractory B-cell. However, the use of autologous T cells has limitations: variable quality of collected effector T cells, ...
| Title translation | Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives. |
|---|---|
| Abstract | Immunotherapy with chimeric antigen receptor engineered-T cells (CAR-T) has revolutionized the landscape of treatment of relapsed or refractory B-cell. However, the use of autologous T cells has limitations: variable quality of collected effector T cells, duration of the process sometimes incompatible with uncontrolled hemopathy, limited number of available CAR cells, sometimes fatal toxicities, extremely high cost. Natural Killer (NK) cells are an interesting alternative to T cells. NK cells are very powerful cytotoxic effectors that have demonstrated an anti-tumor effect after haploidentical hematopoietic stem cells transplantation or in adoptive cell therapy against a number of solid or hematological tumors. Mainly, they can be used in allogeneic situations without causing major toxic side effects. The sources of NK cells are multiple: cell line, cord blood, peripheral blood, induced pluripotent stem cells. Recent advances in manufacturing engineered CAR-NK cells make it possible to promote antibody-dependent cell-mediated cytotoxicity (ADCC), as well as the activation and persistence of these cells, notably via the cytokine Il-15. The majority of the reports on CAR-NK cells concern pre-clinical or early clinical trials. However, the many advantages of "off-the-shelf" allogeneic CAR-NK cells provide great potential in cancer treatments. |
| MeSH term(s) | Allogeneic Cells/cytology ; Allogeneic Cells/immunology ; Antibody-Dependent Cell Cytotoxicity ; Blood Cells ; Cell Engineering ; Cell Line ; Fetal Blood/cytology ; Hematologic Neoplasms/immunology ; Hematologic Neoplasms/therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy, Adoptive/methods ; Induced Pluripotent Stem Cells/cytology ; Killer Cells, Natural/cytology ; Killer Cells, Natural/immunology ; Killer Cells, Natural/transplantation ; Lymphocyte Activation ; Neoplasms/immunology ; Neoplasms/therapy ; Receptors, Chimeric Antigen/immunology ; T-Lymphocytes/cytology ; T-Lymphocytes/immunology ; T-Lymphocytes/transplantation |
| Chemical Substances | Receptors, Chimeric Antigen |
| Language | French |
| Publishing date | 2021-12-17 |
| Publishing country | France |
| Document type | Journal Article ; Review |
| ZDB-ID | 213270-9 |
| ISSN | 1769-6917 ; 0007-4551 |
| ISSN (online) | 1769-6917 |
| ISSN | 0007-4551 |
| DOI | 10.1016/j.bulcan.2021.06.007 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.15: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.